Portola Pharmaceuticals submits New Drug Application to FDA for Betrixaban
Portola announced it has submitted a NDA to the FDA seeking approval to market betrixaban for extended-duration prophylaxis of venous thromboembolism in acute medically ill patients with risk factors for VTE. Betrixaban is an oral, once-daily Factor Xa inhibitor anticoagulant. October 25, 2016